OCULAR THERAPEUTIX, INC

For the period ended Dec 31, 2025. Filed Feb 5, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 5, 2026

OCUL$6.61-3.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)


· · Year Ended December 31,
· ·
· · 2025 · · 2024 · · 2023
Revenue:
Product revenue, net	$51,823	$63,461	$57,870
Collaboration revenue	128	262	573
Total revenue, net	51,951	63,723	58,443
Costs and operating expenses:
Cost of product revenue	6,574	5,626	5,281
Research and development	197,096	127,635	61,055
Selling and marketing	53,922	41,590	40,549
General and administrative	64,376	60,653	33,940
Total costs and operating expenses	321,968	235,504	140,825
Loss from operations	(270,017)	(171,781)	(82,382)
Other income (expense):
Interest income	18,355	20,282	3,983
Interest expense	(11,835)	(13,577)	(11,338)
Change in fair value of derivative liabilities	(2,471)	(480)	(5,188)
Gains and (losses) on extinguishment of debt, net	—	(27,950)	14,190
Other gains (expenses)	29	—	(1)
Total other income (expense), net	4,078	(21,725)	1,646
Net loss	$(265,939)	$(193,506)	$(80,736)
Net loss per share, basic	$(1.42)	$(1.22)	$(1.01)
Weighted average common shares outstanding, basic	187,241,483	158,265,162	79,827,362
Net loss per share, diluted	$(1.42)	$(1.22)	$(1.02)
Weighted average common shares outstanding, diluted	187,241,483	158,265,162	85,596,594

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.